4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso(Université Paris Cité), E.P. Winer(Dana-Farber Cancer Institute), Fabrice André(Inserm), Gertrude Nakigudde(Uganda Cancer Institute), Giuseppe Curigliano(European Institute of Oncology), S. Johnston(Royal Marsden NHS Foundation Trust), A. Costa(European School of Oncology), Smruti Koppikar(Bombay Hospital), Danielle Spence(Breast Cancer Network Australia), D.A. Vorobiof, Efthymios Papadopoulos(Louisiana State University), B.V. Offersen(Aarhus University Hospital), Nadia Harbeck(Breast Center), Matti Aapro(Breast Center), B. Aguilar Lopez(Universidad Latinoamericana), B. Xu(Sonnenhalde (Switzerland)), Maria João Cardoso(Champalimaud Foundation), Larry Norton(Memorial Sloan Kettering Cancer Center), P.A. Francis(Peter MacCallum Cancer Centre), I.E. Krop(Dana-Farber Cancer Institute), Nagi S. El Saghir(American University of Beirut Medical Center), Bella Kaufman(Sheba Medical Center), Laura Biganzoli(Hospital of Prato), Javier Cortés(Villa Maria Hospital), Véronique Dièras(Institut Curie), Shinji Ohno(National Hospital Organization Kyushu Cancer Center), Elżbieta Senkus(Gdańsk Medical University), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Frédérique Penault‐Llorca(Institut Claudius Regaud), L.A. Carey(University of North Carolina Health Care), Karen A. Gelmon(BC Cancer Agency), Olivia Pagani(European University Cyprus), Jonas Bergh(Karolinska University Hospital), H.S. Rugo(UCSF Helen Diller Family Comprehensive Cancer Center), Lesley Fallowfield(Brighton and Sussex Medical School), C.B. Boers-Doets, Aleix Prat(Breast Cancer Research Foundation), Musa Mayer, G. W. Sledge(Stanford Medicine), Shani Paluch–Shimon(Hebrew University of Jerusalem), C.H. Barrios, Christoph Thomssen(University Hospital in Halle)
Cited by 1,189
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k